OR WAIT null SECS
Check out the latest features and columns!
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic.
October's Executive Profile features Imvax CEO John Furey
How can clinical trials be designed to best study therapies for treating long COVID?
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.
Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
October 19, 2021
Leveraging RWD can lessen the strain normally put on investigators and sites.
October 15, 2021
Erica Schultz, CMO of RAIN Group, provides insight on how to breakthrough to make connections and build rapport with HCPs in a time when face-to-face and other interactions have decreased significantly.
Word is out that the White House will name cardiologist and research pro Robert Califf to the top FDA job, a position he held for almost a year at the end of the Obama administration. But he may face opposition in the Senate.
While advanced therapy medicinal products (ATMPs) hold great promise, the path to exploiting the technology has been challenging. Christian K. Schneider outlines the five strategies that must be considered to increase the success rates of development programs, while avoiding some of the common pitfalls.
Soaring prescription drug costs and access to healthcare are two of the industry’s primary challenges. But with the widespread acceptance and adoption of new healthcare technologies, many pharma and health tech companies are stepping up to address these issues.
October 14, 2021
Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Michael Petroutsas, Senior Vice President and Head of GSK’s US Oncology Business Unit, talks about how his background has taught him the importance of connecting with patients on their level and how he brings that mentality to GSK.
Clay Hausmann describes how Almirall is weeding out uncertainty to sow the seeds of data-driven digital transformation.
Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.
October 13, 2021
Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
